STP 125G
Alternative Names: STP-125GLatest Information Update: 19 Jul 2024
At a glance
- Originator Sirnaomics
- Class Antihyperlipidaemics; Cardiovascular therapies; Peptide drug conjugates; Small interfering RNA
- Mechanism of Action Apolipoprotein C-III inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cardiovascular disorders; Hypertriglyceridaemia
Most Recent Events
- 12 Jul 2024 Preclinical trials in Cardiovascular disorders in USA (unspecified route)
- 12 Jul 2024 Sirnaomics announces intention to submit an Investigational New Drug application to the US FDA for Cardiovascular disorders
- 12 Jul 2024 Pharmacodynamics and adverse events data from a preclinical study in Cardiovascular disorders released by Sirnaomics